The Asia-Pacific Antibody Drug Conjugates Market was worth USD 1.52 billion in 2018 and estimated to be growing at a CAGR of 28.56%, to reach USD 5.34 billion by 2023. Antibody drug conjugate(ADC) is a biologically active drug used as targeted therapy in the treatment of cancer that is highly potent drugs of biopharmaceutical industry. These drugs are chemically complex molecules intended to kill the cancer cells in the body which composed of antibody that is biologically linked to anticancer drugs. These drugs target multiple pathways and reduces the risk of developing treatment resistant disorders in the body.
By the mechanism of action, the drugs are segmented into IgG1 antibodies and HER2 antibodies which affect different pathogens like bacteria, fungi and virus in the body. Antibody drug conjugates are widely accepting by several small and big pharmaceutical companies that is filling gaps between many oncology product pipelines. These drugs are also used in many other applications like metabolic disorders, cardiovascular, central nervous system, life science research tools, medical imaging and vaccines.
Factors like rise in cancer incidences, changing lifestyles, high investments by the companies in the pipeline analysis, cancer killing ability and research development of ADCs, growing biomedical industry, new product innovations and technology advancements are driving the Asia-Pacific Antibody Drug Conjugates Market. However, high cost of production of ADCs and stringent regulations for the product approval are hindering the growth of the market.
The Asia-Pacific Antibody Drug Conjugates Market is segmented on the basis of pipeline analysis, end-user and region. Based on the pipeline analysis, the market is segmented into phase, mode of action, technology and linker. The mode of action segment is sub-segmented into IgG1 antibodies and HER2 antibodies. The technology segment is further segmented into Seattle genetics, Immunogen and Immunomedics. On the basis of End-user, the market is segmented into research institutes, hospitals, clinics and others. The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Asia-Pacific is the fastest growing region with a high CAGR owing to the rise in prevalence of cancer, growing demographics and emerging economies like China and India.
Major companies dominating the Asia-Pacific Antibody Drug Conjugates Market are Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Pipeline Analysis
5.1.1 Introduction
5.1.2 Phase
5.1.3 Mode of action
5.1.3.1 IgG1 antibodies
5.1.3.2 HER2 antibodies
5.1.4 Technology
5.1.4.1 Seattle Genetics
5.1.4.2 Immunogen
5.1.4.3 Immunomedics
5.1.5 Linker
5.1.6 Y-o-Y Growth Analysis, By Pipeline Analysis
5.1.7 Market Attractiveness Analysis, By Pipeline Analysis
5.1.8 Market Share Analysis, By Pipeline Analysis
5.2 End-user
5.2.1 Introduction
5.2.2 Research institutes
5.2.3 Hospitals
5.2.4 Clinics
5.2.5 Others
5.2.6 Y-o-Y Growth Analysis, By End-user
5.2.7 Market Attractiveness Analysis, By End-user
5.2.8 Market Share Analysis, By End-user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Pipeline Analysis
6.1.3.3 By End-user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Pipeline Analysis
6.1.4.3 By End-user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Pipeline Analysis
6.1.5.3 By End-user
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Seattle Genetics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Genentech
8.3 Takeda Pharmaceuticals
8.4 F. Hoffmann-La Roche
8.5 Bayer Healthcare
8.6 Agensys, Inc.,
8.7 Immunogen
8.8 Novartis
8.9 Oxford Biotherapeutics
8.10 Synthon Biopharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
